Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572297 | PMC |
| http://dx.doi.org/10.36416/1806-3756/e20180352 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study.
J Allergy Clin Immunol Pract
November 2024
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.
Article Synopsis
- In February 2024, the FDA approved omalizumab for food allergy treatment, following positive results from the OUtMATCH phase 3 clinical trial.
- The trial showed significant effectiveness in desensitizing patients to multiple allergens, although some participants did not respond and fewer tolerated all three food allergens compared to single ones.
- Clinicians are expected to have questions about patient selection and treatment management, indicating a need for further research to enhance real-world application and ensure high-quality outcomes.
Biologics in T2 Severe Asthma: Unveiling Different Effectiveness by Real-World Indirect Comparison.
J Clin Med
August 2024
Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy.
: Indirect comparison among biologics in severe asthma (SA) is a challenging but desirable goal for clinicians in real life. The aim of the study is to define characteristics of a biologic-treated T2-driven-SA population and to evaluate the effectiveness of biologic treatments in a real-world setting by variation in intra/inter-biologic parameters in an up to 4-year follow-up. : Demographic, clinical, functional, and biological characteristics were evaluated retrospectively in 104 patients recruited until July 2022 at baseline (T0) and over a maximum of 4 years (T4) of biologic therapy (omalizumab/OmaG = 41, from T0 to T4, mepolizumab/MepoG = 26, from T0 to T4, benralizumab/BenraG = 18, from T0 to T2, and dupilumab/DupiG = 19, from T0 to T1).
View Article and Find Full Text PDFWhat can be learned from real-world data about chronic spontaneous urticaria?
Allergy Asthma Proc
July 2024
Division of Statistics, Firat University Faculty of Science, Elazig, Turkey.
Article Synopsis
- Chronic spontaneous urticaria (CSU) shows varied patient responses to the treatment with omalizumab, highlighting the need for predictive factors for treatment efficacy.
- A study from 2015-2022 at Pamukkale University examined clinical characteristics and several biomarkers (like eosinophils, total IgE) to see how they relate to treatment success.
- Results indicated that patients with total IgE levels ≤ 30 IU/L had a significantly lower response rate, and non-responders had higher systemic inflammation markers compared to responders, suggesting potential predictors for treatment outcomes.
ChatGPT as a New Tool to Select a Biological for Chronic Rhino Sinusitis with Polyps, "Caution Advised" or "Distant Reality"?
J Pers Med
May 2024
Otorhinolaryngology Section, Biomedicine, Neuroscience and Advanced Diagnosics Department (BiND), University of Palermo, Via del Vespro 129, 133, 90127 Palermo, Italy.
ChatGPT is an advanced language model developed by OpenAI, designed for natural language understanding and generation. It employs deep learning technology to comprehend and generate human-like text, making it versatile for various applications. The aim of this study is to assess the alignment between the Rhinology Board's indications and ChatGPT's recommendations for treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP) using biologic therapy.
View Article and Find Full Text PDFCurrent options in the management of tree nut allergy: A systematic review and narrative synthesis.
Pediatr Allergy Immunol
May 2024
Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
Tree nut allergy is a lifelong and potentially life-threatening condition. The standard of care is strictly avoiding the culprit nut and treating accidental reactions symptomatically. To evaluate potential therapeutic options for desensitizing patients with IgE-mediated tree nut allergy, we systematically searched three bibliographic databases for studies published until January 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!